Oropharyngeal Cancer Market expected to rise | Companies – AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, expected to boost the market

 Breaking News
  • No posts were found

Oropharyngeal Cancer Market expected to rise | Companies – AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, expected to boost the market

June 08
11:45 2023
Oropharyngeal Cancer Market expected to rise | Companies - AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, expected to boost the market
Oropharyngeal Cancer Market
DelveInsight’s “Oropharyngeal Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Oropharyngeal Cancer market growth is driven by factors like increase in the prevalence of Oropharyngeal Cancer, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Oropharyngeal Cancer market report also offers comprehensive insights into the Oropharyngeal Cancer market size, share, Oropharyngeal Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Oropharyngeal Cancer market size growth forward. 

Some of the key highlights from the Oropharyngeal Cancer Market Insights Report:

  • Several key pharmaceutical companies, including AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals, Sanofi, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook. 
  • The total Oropharyngeal Cancer market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Oropharyngeal Cancer market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Oropharyngeal Cancer Market Landscape

Oropharyngeal Cancer Overview 

Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal Cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs. And although rare, lymphoma, or cancer affecting cells in the lymphatic system, can also occur at the base of the tongue and tonsils, which are made up of lymph tissue. Symptoms include a sore throat that doesn’t go away; a lump in the throat, mouth or neck; coughing up blood; white patch in the mouth and other symptoms. The stages of oropharyngeal cancer span from Stage I (best prognosis) to Stage IV (worst prognosis). Oropharyngeal Cancer diagnosis often begins with a physical exam conducted by doctor, or sometimes dentist, to check for any signs of abnormality such as a sore or lump in mouth or swollen lymph nodes in neck. Treatment for oropharyngeal cancer depends on several factors, including but not limited to: type of cancer, size of the tumor and location of the cancer, lymph nodes, speech and swallow function, and the patient’s overall medical condition.

Do you know the treatment paradigms for different countries? Download our Oropharyngeal Cancer Market Sample Report

Oropharyngeal Cancer Epidemiology Segmentation 

DelveInsight’s Oropharyngeal Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Oropharyngeal Cancer historical patient pools and forecasted Oropharyngeal Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Oropharyngeal Cancer Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Oropharyngeal Cancer Prevalence 
  • Age-Specific Oropharyngeal Cancer Prevalence 
  • Gender-Specific Oropharyngeal Cancer Prevalence 
  • Diagnosed and Treatable Cases of Oropharyngeal Cancer

Visit for more @ Oropharyngeal Cancer Epidemiological Insights

Oropharyngeal Cancer Treatment Market 

The Oropharyngeal Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Oropharyngeal Cancer market trends by analyzing the impact of current Oropharyngeal Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Oropharyngeal Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Oropharyngeal Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Oropharyngeal Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Oropharyngeal Cancer Key Companies

  • AstraZeneca
  • ISA Pharmaceuticals
  • Pfizer
  • Bristol Myers Squibb
  • Advaxis
  • PDS Biotechnology
  • Debiopharm
  • Merck KGaA
  • Regeneron Pharmaceuticals
  • Sanofi

Oropharyngeal Cancer Therapy Assessment

Cisplatin: AstraZeneca

Cisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells’ genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.

ISA101B: ISA Pharmaceuticals

ISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.

For more information, visit Oropharyngeal Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Oropharyngeal Cancer Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Oropharyngeal Cancer, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Oropharyngeal Cancer epidemiology in the 7MM
  • Oropharyngeal Cancer marketed and emerging therapies 
  • Oropharyngeal Cancer companies
  • Oropharyngeal Cancer market drivers and barriers 

Key Questions Answered in the Oropharyngeal Cancer Market Report 2032:

  • What was the Oropharyngeal Cancer market share distribution in 2019, and how would it appear in 2032?
  • What is the total Oropharyngeal Cancer market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Oropharyngeal Cancer market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Oropharyngeal Cancer market projected to expand at 7MM?

Table of Contents:

1 Oropharyngeal Cancer Market Key Comprehensive Insights 

2 Oropharyngeal Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Oropharyngeal Cancer

4 Oropharyngeal Cancer Market Analysis Overview at a Glance

5 Executive Summary of Oropharyngeal Cancer

6 Oropharyngeal Cancer Epidemiology and Market Methodology

7 Oropharyngeal Cancer Epidemiology and Patient Population

8 Oropharyngeal Cancer Patient Journey

9 Oropharyngeal Cancer Treatment Algorithm, Oropharyngeal Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Oropharyngeal Cancer Clinical Trials

11 Oropharyngeal Cancer Marketed Therapies 

12 Oropharyngeal Cancer Emerging Therapies

13 Oropharyngeal Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Oropharyngeal Cancer

16 Oropharyngeal Cancer Market Key Opinion Leaders Reviews

18 Oropharyngeal Cancer Market Drivers

19 Oropharyngeal Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Oropharyngeal Cancer Epidemiology 2032

DelveInsight’s “Oropharyngeal Cancer – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Oropharyngeal Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Oropharyngeal Cancer Pipeline 2023

“Oropharyngeal Cancer Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oropharyngeal Cancer market. A detailed picture of the Oropharyngeal Cancer pipeline landscape is provided, which includes the disease overview and Oropharyngeal Cancer treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles